Merck & Co., Inc. (MRK), based in Rahway, New Jersey, is a healthcare company. Valued at $264.2 billion by market cap, the company delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The pharmaceutical giant is expected to announce its fiscal fourth-quarter earnings for 2025 before the market opens on Tuesday, Feb. 3. Ahead of the event, analysts expect MRK to repor ...

记者丨 韩利明 编辑丨季媛媛 1月4日晚间，兴齐眼药（300573.SZ）公告称，0.02%（0.4ml：0.08mg）及0.04%（0.4ml： 0.16mg）硫酸阿托品滴眼液的补充申请获得国家药品监督管理局批准，用于延缓球镜度数 为-1.00D至-4.00D(散光≤1.50D、屈光参差≤1.50D)的6至12岁儿童的近视进展。 当前我国儿童青少年近视问题形势严峻，不仅呈现"低龄、高发、重度"的发展态势，中度、高 度近视增长趋势亦持续显现。兴齐眼药方面指出，此次两款阶梯浓度产品的获批，成为兴齐眼 利好消息迅速传导至资本市场。1月5日兴齐眼药股价直线冲高，最终收涨近5%，报73.68元/ 股；1月6日股价延续上行态势，报74.2元/股收盘，上涨0.71%，总市值达182.85亿元。 药继2024年0.01%浓度硫酸阿托品滴眼液获批后的重要突破，进一步丰富了临床治疗选择。 在业内看来，目前国内外尚无0.02%和0.04%硫酸阿托品滴眼液近视相关适应症产品获批上 市，且兴齐眼药0.01%硫酸阿托品滴眼液（美欧品®）作为国内首款获批用于延缓儿童近视进 展的产品，已积累了稳定的市场份额和临床认可度，这将为两款新品打开 ...

Core Viewpoint - The recent U.S. military action in Venezuela, which holds the world's largest proven oil reserves, has created significant geopolitical implications for global equity markets, particularly affecting sectors like defense, technology, and healthcare [2][3]. Energy Sector Impact - Venezuela possesses approximately 303 billion barrels of proven oil reserves, accounting for 17-18% of global oil reserves, but its crude production has fallen to below 2 million barrels per day from about 3.5 million barrels per day due to infrastructure issues and sanctions [4]. - The U.S. military intervention has renewed interest in Venezuelan crude flows, but analysts caution that any significant increase in production will require years of investment and political stabilization [5][6]. - Major U.S. energy companies like Chevron, which operates in Venezuela under a special license, have seen limited immediate impact from the situation, as Venezuelan operations contribute only a small portion to overall revenues [7]. Defense Sector Benefits - Defense stocks are expected to be the primary beneficiaries of heightened geopolitical tensions, as historical patterns show increased military spending during such periods [9]. - Companies like Lockheed Martin and Northrop Grumman are likely to benefit from long-term contracts and increased order backlogs due to the current geopolitical climate [10][11]. Technology Sector Dynamics - Technology stocks typically respond to geopolitical shocks through risk sentiment rather than direct revenue exposure, with initial pressure on high-value stocks [12]. - Over the medium term, companies like CrowdStrike Holdings and Palo Alto Networks may benefit from increased demand for cybersecurity solutions as security-driven spending rises [12]. Healthcare Sector Resilience - Healthcare equities tend to remain stable during geopolitical uncertainty due to the inelastic nature of demand, with pharmaceutical and medical device companies being less affected by conflicts [13]. - Large healthcare firms and those involved in medical readiness are expected to benefit as governments focus on biosecurity and supply-chain resilience during global instability [13]. Conclusion on Market Dynamics - The evolving geopolitical landscape suggests that defense stocks will benefit most directly, while select technology firms will gain over time through security-related demand, and healthcare will act as a stabilizing force in the market [14][15].

Core Insights - The medical sector is increasingly adopting artificial intelligence (AI), enhancing drug synthesis, device creation, and diagnostic accuracy [2][3] Group 1: Eli Lilly and Co. (LLY) - Eli Lilly focuses on cardiometabolic health, neuroscience, oncology, and immunology, which are high-growth areas with significant commercial potential [5] - Demand for LLY's GLP-1 drugs, Mounjaro and Zepbound, remains strong, contributing to robust sales in 2025 [6] - LLY is advancing its pipeline with an oral GLP-1 obesity pill, orforglipron, expected to launch next year [7] - Eli Lilly is collaborating with OpenAI for novel medicine discovery and invested $409 million in Genetic Leap for AI-driven drug discovery [7] - The company is building a supercomputer with NVIDIA to enhance its AI capabilities, with expected revenue and earnings growth rates of 22.3% and 41.3% respectively for the current year [8] - LLY has a return on equity (ROE) of 109.5%, significantly higher than the industry average of 37% [9] Group 2: Medtronic plc (MDT) - Medtronic is integrating AI into its solutions to improve patient care and operational efficiency, including an AI-powered surgical video management platform [10] - The GI Genius project enhances colorectal cancer detection, increasing survival rates by identifying polyps that may be missed [11] - Medtronic's partnerships leverage AI to optimize cardiac procedures and improve diagnostic precision, driving growth in the medtech sector [12] - The company has an expected revenue and earnings growth rate of 7.5% and 2.7% respectively for the current year [14] - MDT has a ROE of 14.9%, outperforming the industry average of -2.5% [14] Group 3: Intuitive Surgical Inc. (ISRG) - Intuitive Surgical is embedding AI into its robotic systems, providing objective performance indicators for surgeons [15] - The company is piloting telecollaboration for remote surgical support, enhancing training and decision-making [16] - ISRG's revenue and earnings growth rates are expected to be 14.3% and 11.1% respectively for the current year [19] - ISRG has a ROE of 15.1%, compared to the industry's ROE of -18.7% [19] Group 4: Regeneron Pharmaceuticals Inc. (REGN) - Regeneron utilizes AI and machine learning for drug target identification, clinical trial optimization, and precision medicine [20] - The company has seen revenue growth driven by strong performance from Dupixent and Libtayo, despite declining sales of Eylea [21] - REGN's expected revenue and earnings growth rates are 4.9% and -0.4% respectively for the current year [23] - REGN has a ROE of 13.8%, significantly higher than the industry's ROE of -65.41% [23] Group 5: Johnson & Johnson (JNJ) - Johnson & Johnson's MedTech division is focused on AI technologies for surgical robotics and digital surgery analytics [24] - The company has developed the Ottava robotic surgery platform and the Caresurgical/VELYS digital surgery systems, enhancing procedure planning [25] - JNJ has an expected revenue and earnings growth rate of 5% and 5.7% respectively for the current year [26] - JNJ has a ROE of 32.7%, compared to the industry's ROE of 37% [26]

Indian courts take a strict but balanced approach to pharmaceutical patents. They closely scrutinize drug patents to prevent evergreening, while protecting genuine innovation. This approach was firmly set out in the 2013 Novartis-Glivec ruling, where Novartis AG sought a patent for its cancer drug Glivec (imatinib mesylate), claiming it was a new form of the cancer drug imatinib. The application was rejected for failing to show proven therapeutic improvement, a decision later upheld by the Supreme Court. ...

早上开车的时候，下意识把频率调到了FM88.7，广播里只传来一片滋滋拉拉的静电噪声。 恍惚间才惊觉，那句熟悉的Never Stop The Beat，早已迎来了Stop的时刻。 HIT FM和2025年一道，都在悄无声息的告别里，彻底翻篇。 无论上一年的投资之路是顺风顺水、得心应手，还是磕磕绊绊、留有遗憾，时间的河流从不停歇，已经载着我们抵达了新 的渡口。 在大盘火热开门红、沪指破纪录13连阳刷新十年新高之际，每位投资者心中都绕不开一个核心疑问： 2026年的市场机会还会延续吗？我们又该如何布局？ 今天，笔者带上公司的年度权益策略，和大家一起聊一聊。 01 新路标 2026年的两大宏观叙事 大家对去年市场最深的感受，莫过于分化与轮动。而公司年度权益策略定的标题是：《走向2026：城头变幻大王旗》。 这句诗出自鲁迅《无题·惯于长夜过春时》，放到权益投资的语境里，大家可以这么理解： 市场的分化趋势仍会延续，主线轮动的节奏可能更快，投资的难度悄然提升。 海外方面，美国正通过构建技术联盟、强化出口管制等方式巩固领先优势；国内则在加速推进AI+战略，让人工智能深度 融入智能制造、智慧医疗、消费升级等各个领域。 这种大国 ...

Core Insights - FedEx is expanding its B2B shipping strategy, which has contributed to nearly half of its revenue growth in the recent quarter, particularly in the automotive and healthcare sectors [3][6] - The company is focusing on specific industries by deploying dedicated leadership teams and resources, including a new data center sales vertical to support existing and new customers [3] - FedEx is enhancing its capabilities in the healthcare sector by allowing shippers to set their own rules for package intervention and monitoring, and has launched a program to create custom standard operating procedures with pharmaceutical shippers [6] Industry Focus - The automotive vertical has seen incremental business growth, exemplified by FedEx's relationship with BMW Group, which values the carrier's global reliability and service for time-critical deliveries [6] - FedEx is also targeting the data center industry, which is experiencing rapid growth and demands precision in logistics, an area where FedEx claims to excel [4] - The company is working with U.S. e-commerce players, such as Wayfair, to improve customer experience by reducing tracking data outages and enhancing order visibility [4]

千金药业(600479.SH)公告称，公司及其子公司千金湘江药业近日收到国家药品监督管理局核准签发的 地屈孕酮片、巴瑞替尼片（4mg、2mg）与达格列净片（5mg、10mg）的《药品注册证书》。这些药品 的获批将进一步丰富公司产品管线，有利于可持续发展。但需注意药品生产和销售受政策、市场环境等 因素影响，存在不确定性。 ...

Core Insights - The training course titled "The Applications of Nanoparticles in the Pharmaceutical and Biomedical Industries" is scheduled for March 11th - 12th, 2026, and aims to provide an in-depth understanding of nanoparticle technology and its applications in these industries [1][2]. Industry Overview - Nanoparticles are increasingly recognized for their ability to interact with biological systems at the molecular level, making them valuable in drug delivery, diagnostics, and therapeutic innovations [3]. - The course will cover various types of nanoparticles, including liposomes, polymeric nanoparticles, and metallic nanoparticles, and their specific applications in pharmaceutical, medtech, and biotech industries [4]. Course Content - Key topics include: - Overview of nanotechnology and its significance in pharmaceuticals and biomedicine [7]. - Characterization of nanoparticles, including size, shape, and surface properties [8]. - Applications of nanoparticles in drug delivery, diagnostics, imaging, and cancer therapy [11]. - Regulatory and safety considerations for nanoparticle-based pharmaceuticals [11]. - Future trends and innovations in nanoparticle research and development [12]. Target Audience - The course is designed for a diverse group of professionals, including pharmaceutical scientists, biomedical engineers, drug development professionals, regulatory affairs specialists, and clinical researchers [6]. Expert Insights - The course will be led by Mohammed Alkattan, who has extensive experience in the development of nanoparticles for drug delivery and clinical applications [12][13].

Core Insights - Oculis Holding AG's neuroprotective candidate Privosegtor has received Breakthrough Therapy Designation from the FDA for the treatment of optic neuritis, highlighting its potential as a first-of-its-kind therapy in this area [1][7]. Company Overview - Oculis is a global biopharmaceutical company focused on innovations in neuro-ophthalmology and ophthalmology, with a late-stage clinical pipeline that includes Privosegtor, OCS-01, and Licaminlimab [15]. Product Details - Privosegtor is a novel peptoid small molecule designed to penetrate both the blood-brain and retinal barriers, potentially addressing significant unmet medical needs in optic neuropathies, with a market opportunity estimated at $7 billion in the U.S. alone [2][5]. - The drug has shown substantial improvements in visual function, with an average gain of 18 letters in Low Contrast Visual Acuity (LCVA) compared to placebo in the Phase 2 ACUITY trial [4][7]. Clinical Trial Insights - The ACUITY trial demonstrated that Privosegtor not only improved visual function but also preserved anatomical structures of the retina and optic nerve, indicating its neuroprotective potential [3][4]. - The trial involved 36 patients with acute optic neuritis, showing that those treated with Privosegtor alongside IV methylprednisolone experienced significant visual improvements [12]. Regulatory and Market Implications - Following a successful meeting with the FDA, Oculis initiated the PIONEER program, which includes three pivotal trials aimed at supporting registration plans for Privosegtor in optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION) [5][6]. - The unmet medical needs in these conditions are significant, as there are currently no approved neuroprotective therapies available [10][11].